Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients

Turkish Journal of Gastroenterology

Volumn 23, Issue 5, 2012, Pages 538-545

  Arabul, Mahmut ^a   Aslan, Fatih ^a   Alper, Emrah ^a   Akpinar, Zehra ^a   Çelik, Mustafa ^a   Kandemir, Altay ^a   Vatansever, Sezgin ^a   Ünsal, Belkis ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Chronic hepatitis C; Fibrosis; Non invasive tests; Non sustained viral response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENDER; HEPATITIS C; HUMAN; LIVER EXAMINATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INVASIVE LIVER FIBROSIS TEST; NON INVASIVE MEASUREMENT; PREDICTOR VARIABLE; RACE; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; VIRAL LOAD; YOUNG ADULT;

EID: 84871175899     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2012.0358     Document Type: Article

References (28)

1. Dienstage JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: 152-60.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52. (Pubitemid 32634271)
3. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2009; 49: 1335-74.
4. Sánchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60. (Pubitemid 44142452)
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
7. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99: 1160-74. (Pubitemid 38917824)
8. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with chronic hepatitis C virus-related chronic liver disease. Arc Intern Med 2003; 163: 218-24. (Pubitemid 36120190)
9. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26. (Pubitemid 36919874)
10. Poynard T, Bedossa P, METAVIR and CLINIVIR Cooperative Study Groups. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepat 1997; 4: 199-208. (Pubitemid 127733511)
11. Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005; 25: 52-64. (Pubitemid 40322350)
12. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J. Hepatol 1995; 22: 696- 9.
13. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-89. (Pubitemid 46763278)
14. Asselah T, Biéche I, Paradis V, et al. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007; 27: 13-27.
15. Lamn SL, Tram T, Zein NN. AASLD 2007: The future of hepatitis C. Therapeutics. 2007{cited 2007 December 17}. Available from://cme.medscape.com/ viewprogram/8292.pdf
16. Regev A, Behro M, Jeffers LJ, et al. Sampling error and intra observer variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
17. Cadranel IF. [Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future]. Gastroenterol Clin Biol 2002; 26: 823-4.
18. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57. (Pubitemid 37466971)
19. Van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: questions and answers. Semin Liver Dis 1995; 15: 340-59.
20. Toniutto P, Fabris C, Bitetto D, et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol 2007; 22: 1904-8. (Pubitemid 47525062)
21. Abdo AA, Al Swat K, Azzam N, et al. Validation of three noninvasive laboratory variables to predict significant fibrosis and cirrhosis in patients with chronic hepatitis C in Saudi Arabia. Ann Saudi Med 2007; 27: 89-93. (Pubitemid 46864087)
22. Parise ER, Oliveira AC, Figueiredo-Mendes C, et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006; 26: 1095-9. (Pubitemid 44548838)
23. Nachnani JS, Gidwani R, Sadeddin E, et al. Clinicopathological predictors to predict sustained viral response rates in patients with chronic hepatitis C infection. Indian J Gastroenterol 2007; 26: 279-82. (Pubitemid 351629630)
24. Colletta C, Smirne C, Marini C, Pirisi M. Liver biopsy and non-invasive alternatives in relationship to the duration of antiviral treatment for hepatitis C. Letter to Editor. J Clin Gastroenterol 2008; 42: 219-20.
25. Xie Y, Xu DZ, Lu ZM, et al. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open and multicenter controlled trial. Hepatobiliary Pancreat Dis Int 2005; 4: 213-9. (Pubitemid 40790168)
26. Mata-Marín JA, Fuentes-Allen JL, Gaytán-Martínez J, et al. APRI as a predictor of early viral response in chronic hepatitis C patients. World J Gastroenterol 2009; 15: 4923-7.
27. Lim AKP, Patel N, Eckersley RJ, et al. Hepatic vein transit times of a microbubble agent in assessing response to antiviral treatment in patients with chronic hepatitis C. J Viral Hepat 2010; 17: 778-83.
28. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105: 1346-53.